The results showed that even patients with disease that has spread to the brain should be considered for immunotherapy.
One-third of patients with locally advanced non-small cell lung cancer treated with durvalumab developed symptomatic pneumonitis.
The agent has a high affinity and specificity for interleukin-1 beta.
Metformin appeared to increase glucose uptake in lung cancer cells, according to results from a phase II trial.
Sequential afatinib and osimertinib improved median overall survival by almost 3.5 years in patients with EGFR T790M-positive non-small cell lung cancer, with an even greater benefit seen in those with Del19-positive disease.
NLR appeared to be a significant predictor of overall survival, and also showed a trend in favor of progression-free survival, among patients with stage III locally-advanced non-small cell lung cancer.
The study found patients with lung cancer referred to palliative care earlier lived longer.
The findings of a new study presented at ESMO may offer a new treatment for non–small cell lung cancer.
Researchers examined how metformin and TKI therapy did in combatting lung cancer.
Several promising drugs for the treatment of lung cancer have been garnering attention over recent years. These new treatments have been highlighted at conferences and are sure to impact the standard of care.